Get the app!
Back to Trades
Sell4

Lyra Therapeutics, Inc.

LYRA

Total Value
$344.2K
Net $344.2K sold
Sales
$344.2K
6 transactions

Company Information

Ticker Symbol
LYRA
CIK
0001327273

Insider Information

Role
Insider
Location
NEW YORK, NY

Filing Details

Filing Date
Nov 10, 2025
Transaction Date
Nov 6, 2025
Accession Number
0001193125-25-274540
Form Type
4
Net Trading Amount
-$344.2K

Non-Derivative Transactions

DateSecuritySharesPriceTypeValue
Nov 6, 2025Common Stock28,902$5.18Sale$149.7K
Nov 6, 2025Common Stock3,247$5.18Sale$16.8K
Nov 7, 2025Common Stock17,746$4.75Sale$84.2K
Nov 7, 2025Common Stock1,993$4.75Sale$9.5K
Nov 10, 2025Common Stock16,633$4.54Sale$75.5K
Nov 10, 2025Common Stock1,869$4.54Sale$8.5K

Footnotes

  1. (F1)The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.85 to $5.65 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.
  2. (F2)Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS (A), LLC ("Perceptive LS"). Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
  3. (F3)The securities reported in this row are held by the Master Fund.
  4. (F4)The securities reported in this row are held by Perceptive LS.
  5. (F5)The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.61 to $4.9 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.
  6. (F6)The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.5 to $4.675 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.